Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Harshad R. Kulkarni"'
Autor:
Thomas Langbein, Harshad R. Kulkarni, Christiane Schuchardt, Dirk Mueller, Gerd Fabian Volk, Richard P. Baum
Publikováno v:
Diagnostics, Vol 12, Iss 8, p 1926 (2022)
Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG) can lead to xer
Externí odkaz:
https://doaj.org/article/b7604289a7394eff80e2be0d2b0d9cf9
Autor:
Cristina Müller, Aviral Singh, Christoph A. Umbricht, Harshad R. Kulkarni, Karl Johnston, Martina Benešová, Stefan Senftleben, Dirk Müller, Christiaan Vermeulen, Roger Schibli, Ulli Köster, Nicholas P. van der Meulen, Richard P. Baum
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-10 (2019)
Abstract Background For almost a decade, terbium radioisotopes have been explored for their potential theragnostic application in nuclear medicine: 152Tb and 155Tb are the radioisotopes identified for PET or SPECT imaging, while 149Tb and 161Tb have
Externí odkaz:
https://doaj.org/article/7eda5b3c70fa41ca97364e47bb48a567
Autor:
Ameya D. Puranik, MD, FEBNM, Harshad R. Kulkarni, MD, Aviral Singh, MD, Richard P. Baum, MD, PhD
Publikováno v:
AACE Clinical Case Reports, Vol 1, Iss 2, Pp e131-e135 (2015)
ABSTRACT: Objective: Peptide receptor radionuclide therapy (PRRT) with 90Yttrium (90Y)- and 177Lutetium (177Lu)-labeled somatostatin analogs are the accepted standard of care for treatment of metastatic well-differentiated neuroendocrine tumors (NET)
Externí odkaz:
https://doaj.org/article/8ce7ff27748d4ca48c4c10e548484b27
Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer
Autor:
Qingxing Liu, Harshad R. Kulkarni, Tianzhi Zhao, Christiane Schuchardt, Xiaoyuan Chen, Zhaohui Zhu, Jingjing Zhang, Richard P. Baum
Publikováno v:
Clinical Nuclear Medicine.
Autor:
Frankis Almaguel, Franz C Robiller, Aviral Singh, Dirk Mueller, Christiane Smerling, Maythinee Chantadisai, Aleksandr Eismant, Christiane Schuchardt, Jingjing Zhang, Frank Osterkamp, Aileen Hoehne, Dirk Zboralski, Ulrich Reineke, Richard P. Baum, Harshad R. Kulkarni
Publikováno v:
Journal of Nuclear Medicine. 63:415-423
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides for theranostic applications. We present the
Autor:
Tobias Rydén, Michael Pröhl, Dirk Müller, Harshad R. Kulkarni, Peter Bernhardt, Nicholas P. van der Meulen, Jan Rijn Zeevaart, Christiane Schuchardt, Richard P. Baum, Nadezda Gracheva, Pascal V. Grundler, Cristina Müller, Aviral Singh, Roger Schibli, Ulli Köster
Publikováno v:
J Nucl Med
(161)Tb has decay properties similar to those of (177)Lu but, additionally, emits a substantial number of conversion and Auger electrons. The aim of this study was to apply (161)Tb in a clinical setting and to investigate the feasibility of visualizi
Autor:
Harshad R Kulkarni, Dan Rogers, Kevin Maupin, Todd Faasse, Jens Forsberg, Matt DeLong, Brandon Robert Mancini
Publikováno v:
Journal of Clinical Oncology. 41:62-62
62 Background: PET/CT using Ga-68 PSMA-11, which received FDA approval, can detect early biochemical recurrence of prostate cancer at greater sensitivity than conventional imaging, as well as more accurately clinical stage and impact treatment manage
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:1390-1398
To determine prognostic factors and overall survival (OS) in therapy-related myeloid neoplasm (t-MN) of patients after receiving peptide receptor radionuclide therapy (PRRT). All patients treated from February 1999 until September 2019 at our center
Autor:
Christiane Schuchardt, Richard P. Baum, Jingjing Zhang, Harshad R. Kulkarni, Aviral Singh, Qingxing Liu
Publikováno v:
Journal of Nuclear Medicine, 61(11), 1560-1569. Society of Nuclear Medicine and Molecular Imaging
The objective of this retrospective study was to determine the role of F-18-FDG PET/CT in a large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were treated with peptide receptor radionuclide therapy (PRRT) with a long-te
Autor:
Kalevi Kairemo, Martin Bögemann, Jingjing Zhang, Clemens Kratochwil, Irene Virgolini, Rolf Fimmers, Richard P. Baum, Johanna Maffey-Steffan, Hojjat Ahmadzadehfar, Harun Ilhan, Carolin Gerke, Kambiz Rahbar, Levent Kabasakal, Diana Paez, Masha Maharaj, Mike Sathekge, Francisco Osvaldo Garcia-Perez, Harshad R. Kulkarni, Robert Seifert, Hendrik Rathke, Katharina Kessel
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:113-122
Introduction The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving [177Lu]Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH dec